PCSA Stock — Processa Pharmaceuticals Inc.: Cash, EV, Pipeline

Share price

$1.96

Market cap

$5.5M

Cash

$0.2M

Enterprise value

$5.3M

Balance sheet

Cash	$0.2M
Debt	$0.0M
Net cash	$0.2M
Enterprise value	$5.3M
Basic shares	2.8M shares
Fully diluted shares	4.9M shares
Fully diluted market cap	$9.5M
Cash per share	$0.07

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading PCSA daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Oct 13 - Nov 24	PCS6422 and capecitabine	Phase 2	Breast Cancer; TNBC - Triple-Negative Breast Cancer; HER2-negative Breast Cancer	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

VT-7208

Phase 2 · Active Modality: oral small molecule

Target Bruton’s tyrosine kinase (BTK)

Partnerships Vidya: lead asset acquired in Vidya Acquisition (Jul 2026); $200M concurrent private placement funds operations into H2 2029

Indications

Food allergy (Phase 2)
Chronic spontaneous urticaria (CSU) (Phase 2)
Relapsing multiple sclerosis (RMS) (Phase 2)

Catalysts

— second half of 2027
— first half of 2028
— second half of 2028

Status note Majority of resources now focused on VT-7208; Phase 2 proof-of-concept studies being initiated in food allergy and CSU.

PCS6422

Phase 2 · Terminated

Aliases NGC-Cap (PCS6422 + capecitabine)

Target DPD

Partnerships Elion Oncology: license terminated and program returned to Elion (settlement Jul 23, 2026); Processa paid $650k and agreed to grant Elion a 7.5% non-voting equity interest

Indications

Advanced/metastatic breast cancer (Phase 2)

Status note Ongoing NGC-Cap Phase 2 trial being closed following termination of the Elion license agreement and return of the program to Elion.

PCS499

Stage not disclosed · Active

Status note Legacy pharmaceutical asset; development being evaluated, including strategic opportunities to maximize long-term value.

PCS12852

Stage not disclosed · Active

Target 5-HT4 receptor (5HT4 agonist)

Status note Legacy pharmaceutical asset; development being evaluated, including strategic opportunities to maximize long-term value.

PCS11T

Stage not disclosed · Active

Target topoisomerase I (SN38 analog)

Status note Legacy pharmaceutical asset; development being evaluated, including strategic opportunities to maximize long-term value.

Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	PCS6422 and capecitabine
Lead indication	Breast Cancer
Lead phase	Phase 2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06568692	Phase 2	Recruiting	Sponsor	Processa Pharmaceuticals	—	Breast Cancer; TNBC - Triple-Negative Breast Cancer; HER2-negative Breast Cancer	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Processa Pharmaceuticals on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

PCSA — Processa Pharmaceuticals Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials